金纳米微粒作探针共振瑞利散射法测定某些蒽环类抗癌药物

在近中性至弱碱性介质中, 金纳米微粒与表柔比星(EPI)、柔红霉素(DNR)和米托蒽醌(MXT)等蒽环类抗癌药物借静电引力、疏水作用力结合, 形成粒径更大的聚集体, 导致共振瑞利散射(RRS)的显著增强并产生新的RRS光谱, 三种结合产物的最大RRS峰均位于313 nm附近, 并在510～610 nm之间有一宽的散射带. 其散射强度(ΔI)与3种抗癌药物的浓度成正比, 对EPI, DNR和MXT的线性范围分别为0.009～0.50, 0.010～0.70 和0.030～1.20 μg?mL^－1, 它们的检出限(3σ)分别为2.7, 3.1和9.0 ng?mL^－1. 研究了反应产物的吸收、荧光和RRS光谱特征, 适宜的反应条件及分析化学性质, 发展了一种用RRS技术灵敏、简便、快速测定蒽环类抗癌药物的新方法.

Resonance Rayleigh Scattering Method for the Determination of Some Anthracycline Anticancer Drugs with Gold Nanoparticle as Probe

In a neutral or weak alkaline medium, the gold nanoparticle can combine with an anthracycline anticancer drugs such as epirubicin, daunorubicin or mitoxantrone by the virtue of electrostatic and hydrophobic interaction, forming aggregate with bigger diameters. As a result, the resonance Rayleigh scattering (RRS) was enhanced greatly, and a new RRS spectrum appeared. The maximum RRS signals of three ion-association complexes were all located at about 313 nm, and there were another wide scattering strip between 510～610 nm. There was a linear relationship between the RRS intensity and the drug concentration in the range of 0.009～0.5 for epirubicin (EPI), 0.010～0.7 for daunorubicin (DNR) and 0.030～1.2 mg?mL^－1 for mitoxantrone (MXT), respectively. Their detection limits (3σ) for three drugs were 2.7 for epirubicin, 3.1 for daunorubicin and 9.0 ng?mL^－1 for mitoxantrone. In this work, the characteristics of the absorption, fluorescence and RRS spectra, the optimum conditions of the reaction and the properties of analytical chemistry were investigated. A sensitive, simple and new method for the determination of anthracycline anticancer drugs based on RRS has been developed.